「倍通数智」首次递表，中国医疗健康流通数字化管理领导者

Core Viewpoint - The company, Beitong Shuzhi, is a pioneer and leader in digital management of healthcare distribution in China, planning to go public on the Hong Kong Stock Exchange with a strong financial performance and a robust data-driven business model [1]. Financial Performance - In 2024, the company reported revenues of approximately RMB 243 million and a net profit of RMB 49 million, with a year-on-year revenue growth of over 47% in the first half of 2025 [1][5]. - The revenue breakdown for 2024 includes channel data governance services contributing RMB 201.4 million (82.7%), risk management services RMB 39.9 million (16.4%), and management consulting services RMB 2.1 million (0.9%) [3][4]. - The gross profit for 2024 was approximately RMB 130 million, with a gross margin of 53.29% [5][8]. Market Position - According to Frost & Sullivan, the company ranks second among third-party digital service providers in the Chinese pharmaceutical and medical device sector by revenue, capturing a market share of 7.5% [10][11]. - The digital service market for pharmaceutical and medical device companies in China is projected to grow from RMB 56 billion in 2020 to RMB 65 billion in 2024, with a compound annual growth rate (CAGR) of 3.9% [7]. Industry Context - The company is positioned in a growing market, with expectations for the digital service market to reach RMB 98 billion by 2029, reflecting a CAGR of 8.4% from 2024 to 2029 [7]. - The company has established a comprehensive data platform that integrates the entire product lifecycle and facilitates seamless integration across all channels in the pharmaceutical distribution sector [1]. Comparable Companies - Comparable companies in the industry include Yidu Tech, Yimai Tong, and Taimei Medical Technology, with varying market performances and financial metrics [12].